To the Editor, A 31-year-old man was referred to our hospital due to thrombocytopenia and chronic kidney disease (CKD). His thrombocytopenia had been noticed since the age of 6 months, because of the bleeding diathesis. He had neither eczema nor deafness. He had been clinically diagnosed as chronic idiopathic thrombocytopenic purpura. At the age of 21, proteinuria and hematuria appeared, and thereafter his renal function deteriorated gradually. At the referral, his laboratory data were as follows: proteinuria 2.1 g/g creatinine, hematuria (3+), white blood cells 5100/µL, hemoglobin 10.3 g/dL, platelets 8000/µL, total protein 6.7 g/dL, albumin 4.1 g/dL, urea nitrogen 34.2 mg/dL, creatinine 2.92 mg/ dL, C 3 74 mg/dL, C 4 28 mg/dL, CH-50 44.8 U/mL, and IgA 321 mg/dL. His autoantibodies were negative. By obtaining an informed consent from the patient, DNA sequencing analysis was performed using the next generation sequencer, MiSeq (Illumina, San Diego, CA) and TruSight One sequencing kit (Illumina). As a result of the analysis of 4813 genes, a missense mutation (c.223G > A, p.Val75Met) was found in the exon 2 in the WAS gene (Fig. 1) . This mutation has already been reported to be responsible for a cause of X-linked thrombocytopenia (XLT) [1] . He was diagnosed as having XLT.
Mutations in the WAS gene cause either XLT or Wiskott-Aldrich syndrome (WAS). XLT is a mild form of WAS and characterized by congenital thrombocytopenia with small platelets, whereas WAS is associated with severe thrombocytopenia, small platelets, eczema, recurrent infection, and increased susceptibility to lymphoid malignancies. Chronic nephritis, such as IgA nephropathy, has been reported to be accompanied in 5-19% of XLT and WAS patients [1, 2] . Aberrant IgA production is considered to be a cause of chronic nephritis in these patients. In addition, results of recent studies have shown that WAS protein, relating to nephrin and Neph1, acts to the polymerization of actin in podocytes and plays an important role in the development of chronic nephritis [3, 4] . According to the previous studies [1, 2] , a certain number of patients had developed to end-stage renal disease, requiring dialysis therapy. On the other hand, there are several cases in which hematopoietic stem cell transplantation (HSCT) was effective to improve chronic nephritis, as well as thrombocytopenia [5] . HSCT would be a therapeutic option in our case, if renal dysfunction progresses.
When a patient exhibits thrombocytopenia and renal dysfunction, it is important for nephrologists to think of XLT and to consider HSCT as an alternative therapy for CKD.
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